Article
Biochemistry & Molecular Biology
Rita Caridade-Silva, Bruna Araujo, Joana Martins-Macedo, Fabio G. Teixeira
Summary: Preventing degeneration and the loss of dopaminergic neurons in Parkinson's Disease (PD) remains a challenge, and developing disease-modifying approaches is imperative. N-acetylcysteine (NAC) has shown promising potential in preserving the dopaminergic system and modulating PD mechanisms. In this study, NAC enhanced dopaminergic neuron viability and improved motor deficits in a rat model of PD, suggesting that it may serve as a modulator of PD degenerative mechanisms.
Article
Neurosciences
Paolo Solla, Tommaso Ercoli, Carla Masala, Gianni Orofino, Laura Fadda, Davide Giacomo Corda, Ignazio Roberto Zarbo, Mario Meloni, Elia Sechi, Caterina Francesca Bagella, Giovanni Defazio
Summary: This article reports three PD patients who developed a severe withdrawal syndrome after discontinuing the use of rasagiline. The syndrome was characterized by prominent psychiatric disorders and autonomic symptoms, resembling dopamine agonist withdrawal syndrome. This report highlights the importance of closely monitoring PD patients undergoing rasagiline suspension for withdrawal symptoms and provides interesting insights into the role of rasagiline and other MAO-B inhibitors in mood disorders.
Article
Nutrition & Dietetics
Devon J. Fox, Sarah JaeHwa Park, Laurie K. Mischley
Summary: The Mediterranean and Mediterranean-DASH Intervention for Neurodegenerative Delay diets are associated with a reduced risk of Parkinson's disease diagnosis. This study found that higher scores on the MIND and MEDI scales are associated with fewer patient-reported symptoms over time, with the MIND diet being more effective in reducing symptom severity.
Article
Medicine, General & Internal
Puyu Li, Ningdi Luo, Sainan Sun, Yuanyuan Li, Dingding Shen, Xue Zhu, Liche Zhou, Haiyan Zhou, Jun Liu
Summary: The NET-PD study is a clinical trial assessing the long-term neuroprotective effect of intermittent theta burst stimulation (iTBS) in Parkinson's disease (PD) patients. With a sample size of 60 PD patients, the study aims to clarify the clinical improvement and dynamic neuronal changes in PD patients using clinical assessment and multi-modal markers.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Clinical Neurology
C. Warren Olanow, Robert A. Hauser, Daniel J. Burdick, Rohit Dhall, Joy Antonelle de Marcaida, Ramon A. Gil, David L. Kreitzman, Lawrence W. Elmer, Andrew Mcgarry, Karl Kieburtz
Summary: This study found that P2B001 was superior to its individual components in treating Parkinson's disease and had comparable efficacy to marketed doses of pramipexole-ER, but with less worsening of sleepiness and fewer dopaminergic adverse events.
MOVEMENT DISORDERS
(2023)
Article
Food Science & Technology
Yujie Chen, Wuke Yuan, Qi Xu, Manju B. Reddy
Summary: Parkinson's disease (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders with shared molecular mechanisms, and there is currently no effective treatment. However, research suggests that consuming phytochemicals may help delay the progression of these diseases.
JOURNAL OF FUNCTIONAL FOODS
(2023)
Review
Cell Biology
Hao Song, Juanli Chen, Jin Huang, Peng Sun, Yanming Liu, Li Xu, Chuanfei Wei, Xin Mu, Xianjie Lu, Wei Wang, Nan Zhang, Miwei Shang, Mei Mo, Wei Zhang, Hui Zhao, Fabin Han
Summary: Parkinson's disease (PD) is a common neurodegenerative disorder caused by genetic, epigenetic, and environmental factors. Recent advance in genomics and epigenetics have revealed epigenetic mechanisms in PD. These epigenetic modifications include DNA methylation, post-translational histone modifications, chromatin remodeling, and RNA-based mechanisms, which regulate cellular functions in almost all cells. Epigenetic alterations are involved in multiple aspects of neuronal development and neurodegeneration in PD.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Neurosciences
Henri Zenuni, Niccolo Candelise, Piergiorgio Grillo, Clara Simonetta, Roberta Bovenzi, Alberto Ferri, Cristiana Valle, Nicola Biagio Mercuri, Tommaso Schirinzi
Summary: This study suggests that PD patients under different iMAO-B treatments may present distinct profiles of CSF neurodegeneration-related biomarkers. However, larger studies are needed to confirm and extend these initial observations.
JOURNAL OF INTEGRATIVE NEUROSCIENCE
(2022)
Review
Pharmacology & Pharmacy
Xin-xing Yang, Rong Yang, Feng Zhang
Summary: Parkinson's disease is a common and chronic degenerative disease in the central nervous system. The main pathology involves the loss of dopaminergic neurons and the formation of Lewy bodies. The pathogenesis of PD is influenced by various independent factors, and regulating the Nrf2 pathway may be a promising strategy for preventing and treating PD.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Medicine, Research & Experimental
Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren, Pninit Litman
Summary: Despite the superior efficacy of levodopa in reducing motor symptoms of Parkinson's disease, its risk of inducing motor complications necessitates consideration of alternative treatments. P2B001, a combination of pramipexole and rasagiline, shows potential for greater efficacy and better tolerability compared to other approaches. It also maintains a lower risk of motor complications compared to levodopa.
ADVANCES IN THERAPY
(2022)
Article
Multidisciplinary Sciences
J. Brucker Nourse, Shannon N. Russell, Nathan A. Moniz, Kylie Peter, Lena M. Seyfarth, Madison Scott, Han-A Park, Kim A. Caldwell, Guy A. Caldwell
Summary: This study investigates the TNK2 gene variants in Parkinson's disease (PD) patients and their potential impact on dopaminergic neurodegeneration. The findings suggest that TNK2 dysfunction may contribute to PD, possibly through sustained or aberrant activity. The study also highlights the importance of TNK2 and its ortholog SID-3 in coordinating dopaminergic and epigenetic signaling. Experimental results using Caenorhabditis elegans and rat primary neurons demonstrate the neuroprotective effects of TNK2 inhibition and NEDD4 activation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Biochemistry & Molecular Biology
Suman Chowdhury, Robert Ledeen
Summary: In this review, we summarize our findings of a systemic deficiency of ganglioside GM1 in Parkinson's disease (PD) tissues. The deficiency is observed in various neuronal and non-neuronal tissues, which suggests a potential underlying mechanism for loss of neuronal viability and normal functioning. We discuss the causes of these deficiencies and propose GM1 replacement as a potential therapy for PD based on strong evidence from animal studies and clinical trials.
Article
Biochemistry & Molecular Biology
Li Liu, Yi Chen, Rui-Feng Zeng, Yun Liu, Sai-Sai Xie, Jin-Shuai Lan, Yue Ding, Yi-Ting Yang, Jun Yang, Tong Zhang
Summary: The study developed a series of monoamine oxidase-B inhibitors with neuroprotective effects, among which compound 4d showed the most potent inhibitory activity against hMAO-B, exhibiting significant therapeutic efficacy for PD with neuroprotective effects. It also has the potential for treating PD effectively and promising prospects.
BIOORGANIC CHEMISTRY
(2021)
Article
Neurosciences
Heba Fikry, Lobna A. Saleh, Sara Abdel Gawad
Summary: This study investigated the protective influence of curcumin on the cerebellum of rats with rotenone-induced Parkinson's disease. The results showed that curcumin could alleviate degenerative changes and neurotoxic effects in the cerebellum, as well as reduce oxidative stress. This suggests that dietary supplementation of curcumin may have neuroprotective effects against cerebellum-related Parkinson's disease symptoms.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Yuki Kitamura, Mayuko Sakanashi, Azuki Ozawa, Yuri Saeki, Ayano Nakamura, Yuiho Hara, Ken-ichi Saeki, Sakae Arimoto-Kobayashi
Summary: The study found that A. arguta juice has neuroprotective effects in a MPTP-induced PD model in mice, improving MPTP-induced motor impairment and suppressing the reduction of tyrosine hydroxylase-positive neurons in the substantia nigra.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Letter
Clinical Neurology
Nikolai Gil D. Reyes, Daniel G. Di Luca, Vanda McNiven, Anthony E. Lang
Summary: GNB1 encephalopathy is a rare neuro-developmental syndrome caused by pathogenic variants in the GNB1 gene. It is characterized by global developmental delay and co-occurrence of movement disorders, with dystonia being the most common. Other rare phenomenologies include myoclonus, tics, chorea, ataxia, and oculomotor abnormalities. This case report presents a unique phenotype of GNB1 encephalopathy caused by a de novo mutation in exon 11, with symptoms of dystonia, myoclonus, and vertical supranuclear gaze palsy.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Geriatrics & Gerontology
Susanna Lopez, Claudio Del Percio, Roberta Lizio, Giuseppe Noce, Alessandro Padovani, Flavio Nobili, Dario Arnaldi, Francesco Fama, Davide V. Moretti, Annachiara Cagnin, Giacomo Koch, Alberto Benussi, Marco Onofrj, Barbara Borroni, Andrea Soricelli, Raffaele Ferri, Carla Buttinelli, Franco Giubilei, Bahar Guntekin, Gorsev Yener, Fabrizio Stocchi, Laura Vacca, Laura Bonanni, Claudio Babiloni
Summary: This study compared the hubs of interdependencies in elderly individuals with and without Alzheimer's disease dementia (ADD) using rsEEG rhythms. The results showed that ADD patients have lower connectivity centrality and directionality compared to normal elderly individuals.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Letter
Clinical Neurology
Daniel G. Di Luca, Dilinuer Wubuli, Vanda McNiven, Anthony E. Lang
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Stuart H. Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi
Summary: This study evaluated the timing of motor improvement in Parkinson's disease patients with OFF episodes using carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO). Results showed that mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3 at 15 and 30 minutes following the first daily CD/LD dose, and FULL ON was achieved by 6.5% and 41.8% of patients, respectively. With an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7% and 81.0% of patients, respectively. In conclusion, concomitant administration of SL-APO with CD/LD may be beneficial for delayed ON.
NEURODEGENERATIVE DISEASE MANAGEMENT
(2023)
Review
Clinical Neurology
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Cotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung-Faye, Cristian Falup-Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke, K. Ray Chaudhuri
Summary: Levodopa is the gold standard treatment for Parkinson's disease, but it often leads to motor and non-motor fluctuations. Gastrointestinal barriers, such as dysphagia, delayed gastric emptying, and gut dysbiosis, can affect levodopa absorption and response. Managing gastrointestinal dysfunction is crucial for optimizing levodopa therapy.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Davide Martino, Vikram Karnik, Roongroj A. Bhidayasiri, Deborah A. A. Hall, Robert A. Hauser, Antonella M. Macerollo, Tamara M. Pringsheim, Daniel A. Truong, Stewart A. Factor, Matej Skorvanek, Anette Schrag, IPMDS Rating Scales Review Comm
Summary: An International Parkinson and Movement Disorder Society subcommittee aimed to rate the psychometric quality of severity and screening instruments for antipsychotic-associated movement disorders. They identified 23 instruments, of which 7 severity rating instruments and 3 screening instruments were recommended with caveats due to insufficient psychometric properties and long duration of administration. New psychometric studies and revision of existing instruments are recommended to address these caveats and improve the clarity of their nomenclature.
MOVEMENT DISORDERS
(2023)
Review
Clinical Neurology
Stefanie Jost, Marie-Ann Kaldenbach, Angelo Antonini, Pablo Martinez-Martin, Lars Timmermann, Per Odin, Regina Katzenschlager, Rupam Borgohain, Alfonso Fasano, Fabrizio Stocchi, Nobutaka Hattori, Prashanth Lingappa Kukkle, Mayela Rodriguez-Violante, Cristian Falup-Pecurariu, Sebastian Schade, Jan Niklas Petry-Schmelzer, Vinod Metta, Daniel Weintraub, Guenther J. Deuschl, Alberto J. Espay, Eng-King Tan, Roongroj Bhidayasiri, Victor S. C. Fung, Francisco Cardoso, Claudia Trenkwalder, Peter Jenner, K. S. Ray Chaudhuri, Haidar Dafsari
Summary: This study reviewed the investigations on drug therapy for Parkinson's disease since 2010 and proposed a new drug conversion formula. These conversion formulas can help us compare drug regimens across different clinical trials. The results are important for studying the pharmacological efficacy of Parkinson's disease treatments as well as other non-pharmacological interventions.
MOVEMENT DISORDERS
(2023)
Letter
Clinical Neurology
Anthony E. Lang
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Donald C. Brien, Heidi C. Riek, Rachel Yep, Jeff Huang, Brian Coe, Corson Areshenkoff, David Grimes, Mandar Jog, Anthony Lang, Connie Marras, Mario Masellis, Paula McLaughlin, Alicia Peltsch, Angela Roberts, Brian Tan, Derek Beaton, Wendy Lou, Richard Swartz, Douglas P. Munoz
Summary: A simple and non-invasive test was developed using video-based eye tracking and machine learning, which showed high sensitivity in detecting the stages of Parkinson's Disease and cognitive impairment. The classifier reached a sensitivity of 83% and a specificity of 78%.
PARKINSONISM & RELATED DISORDERS
(2023)
Editorial Material
Clinical Neurology
Nikolai Gil D. Reyes, Anthony E. Lang
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Letter
Clinical Neurology
Seyedeh Narges Tabatabaee, Sajjad Effat Nejad, Ali Nikkhah, Narges Hashemi, Afagh Alavi, Anthony E. E. Lang, Mohammad Rohani, Maziar Emamikhah
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Review
Clinical Neurology
Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Verin, Wolfgang H. Jost
Summary: Device-aided therapies (DAT), including deep brain stimulation and pump-based continuous dopaminergic stimulation, have significantly improved the clinical management of Parkinson's disease (PD). However, there are disparities in access to DAT, raising concerns about the equal opportunity for advanced PD patients to receive these treatments. Factors such as access to care, referral patterns, physician biases, and patient preferences need to be considered in addressing these disparities.
JOURNAL OF NEURAL TRANSMISSION
(2023)
Article
Clinical Neurology
Daniel G. Di Luca, Carolina Ramirez-Gomez, Jurgen Germann, Brendan Santyr, Alexandre Boutet, Luka Milosevic, Anthony E. Lang, Suneil K. Kalia, Andres M. Lozano, Alfonso Fasano
Summary: This study aimed to evaluate the safety and efficacy of deep brain stimulation on the globus pallidus pars interna and externa in MSA-P patients. The surgery did not result in major complications, but did not provide significant clinical benefit as measured by MDS-UPDRS III.
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
C. Warren Olanow, Robert A. Hauser, Daniel J. Burdick, Rohit Dhall, Joy Antonelle de Marcaida, Ramon A. Gil, David L. Kreitzman, Lawrence W. Elmer, Andrew Mcgarry, Karl Kieburtz
Summary: This study found that P2B001 was superior to its individual components in treating Parkinson's disease and had comparable efficacy to marketed doses of pramipexole-ER, but with less worsening of sleepiness and fewer dopaminergic adverse events.
MOVEMENT DISORDERS
(2023)
Review
Clinical Neurology
Iris Lin, Laura Armengou-Garcia, Sanskriti Sasikumar, Greg Kuhlman, Susan H. Fox, Anthony E. Lang, Alberto J. Espay
Summary: Speech-induced craniofacial myoclonus with stuttering-like dysarthria and speech arrests is a disabling iatrogenic complication in Parkinson's disease that resolves upon amantadine discontinuation. Four of the patients with renal insufficiency were identified as a risk factor.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)